| Abstrakt: |
A recent study conducted by researchers at Chulalongkorn University in Bangkok, Thailand, has explored the potential of a specific immune cell-targeted therapy for sepsis. The study focused on the use of a mitochondrial uncoupling agent called BAM15 to interfere with the energy sources and metabolic processes of macrophages, a type of immune cell. The researchers found that BAM15 particles, when administered to mice with sepsis, reduced the inflammatory response of macrophages and improved their mitochondrial activity, ultimately attenuating the severity of sepsis. These findings suggest that macrophage-targeted therapy using BAM15 particles could be a promising treatment for severe inflammatory diseases like sepsis. [Extracted from the article] |
